Study: NCT05592379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: The IV formulation of psilocybin will be prepared using bulk psilocybin that will satisfy Good Manufacturing Practice (GMP) criteria. The IV psilocybin solution will be prepared under sterile conditions by the University of Wisconsin Pharmaceutical Research Center (PRC).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: The IV formulation of psilocybin will be prepared using bulk psilocybin that will satisfy Good Manufacturing Practice (GMP) criteria. The IV psilocybin solution will be prepared under sterile conditions by the University of Wisconsin Pharmaceutical Research Center (PRC).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Psilocybin
Description: The IV formulation of psilocybin will be prepared using bulk psilocybin that will satisfy Good Manufacturing Practice (GMP) criteria. The IV psilocybin solution will be prepared under sterile conditions by the University of Wisconsin Pharmaceutical Research Center (PRC).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: The IV formulation of psilocybin will be prepared using bulk psilocybin that will satisfy Good Manufacturing Practice (GMP) criteria. The IV psilocybin solution will be prepared under sterile conditions by the University of Wisconsin Pharmaceutical Research Center (PRC).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: The IV formulation of psilocybin will be prepared using bulk psilocybin that will satisfy Good Manufacturing Practice (GMP) criteria. The IV psilocybin solution will be prepared under sterile conditions by the University of Wisconsin Pharmaceutical Research Center (PRC).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Psilocybin
Description: The IV formulation of psilocybin will be prepared using bulk psilocybin that will satisfy Good Manufacturing Practice (GMP) criteria. The IV psilocybin solution will be prepared under sterile conditions by the University of Wisconsin Pharmaceutical Research Center (PRC).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: The IV formulation of psilocybin will be prepared using bulk psilocybin that will satisfy Good Manufacturing Practice (GMP) criteria. The IV psilocybin solution will be prepared under sterile conditions by the University of Wisconsin Pharmaceutical Research Center (PRC).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: Clonidine will be administered orally in a 0.2mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: Clonidine will be administered orally in a 0.2mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: Clonidine will be administered orally in a 0.2mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: Clonidine will be administered orally in a 0.2mg dose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline
Description: The IV placebo (saline) will be prepared under sterile conditions by the University of Wisconsin Pharmaceutical Research Center.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline
Description: The IV placebo (saline) will be prepared under sterile conditions by the University of Wisconsin Pharmaceutical Research Center.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline
Description: The IV placebo (saline) will be prepared under sterile conditions by the University of Wisconsin Pharmaceutical Research Center.